¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"maximal midexpiratory flow rate"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • crude survival rate
    º¸Åë»ýÁ¸À², Á¶»ýÁ¸À²
  • cumulative death rate
    ´©Àû»ç¸Á·ü
  • cumulative incidence rate
    ´©Àû¹ß»ý·ü
  • cumulative survival rate
    ´©Àû»ýÁ¸À²
  • cure rate
    Ä¡À¯À²
  • case fatality rate
    Áõ·ÊÄ¡¸í·ü
  • case morbidity rate
    Áõ·ÊÀÌȯÀ²
  • cause-specific rate
    ¿øÀκ°ºñÀ²
  • cerebral metabolic rate
    ³ú´ë»çÀ²
  • child death rate
    ¼Ò¾Æ»ç¸Á·ü
  • defect rate
    °áÇÔ·ü
  • death rate
    »ç¸Á·ü
  • diffusion rate
    È®»êÀ²
  • disability rate
    Àå¾ÖÀ²
  • disappearance rate
    ¼Ò½Ç·ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • arterial perfusion rate
    µ¿¸Æ°ü·ùÀ²
  • attack rate
    ¹ßº´·ü
  • bacterial growth rate
    ¼¼±ÕÁõ½Ä·ü
  • basal metabolic rate
    ±âÃÊ´ë»çÀ²
  • bed turnover rate
    º´»óȸÀüÀ²
  • birth rate
    Ãâ»ý·ü
  • cardiac rate
    (¢¡heart rate) ½ÉÀå¹Úµ¿¼ö
  • case fatality rate
    Ä¡¸í·ü
  • case morbidity rate
    Áõ·ÊÀÌȯÀ²
  • cause-specific rate
    ¿øÀκ°Æ¯¼öÀ²
  • cerebral metabolic rate
    ³ú´ë»çÀ²
  • child death rate
    À¯¾Æ»ç¸Á·ü
  • completion rate
    ¿Ï¼º·ü
  • concordance rate
    ÀÏÄ¡À²
  • conversion rate
    ÀüȯÀ²
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • rate process
    ¼Óµµ°úÁ¤(áÜöôΦïï).
  • recombination rate
    Àç°áÇÕ·ü(¡­ëÒ).
  • red cell iron renewal rate
    ÀûÇ÷±¸Ã¶±³´ëÀ²(îåúìϹôÑÎßÓÛëÒ).
  • relative metabolic rate
    »ó´ëÀû ´ë»çÀ².
  • relative survival rate
    »ó´ë»ýÁ¸À²
  • relaxation rate
    ÀÌ¿ÏÀ²
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • flow cytometry
    À¯·®¼¼Æ÷°è»ê
  • flow cytometry
    À¯¼Ó ¼¼Æ÷ºÐ¼®¹ý
  • flow encoding axis
    À¯µ¿ ºÎȣȭ Ãà
  • flow meter
    À¯·®(êüÕá)<À¯¼Ó(êüáÜ)>°è(Ìþ).
  • flow meter
    À¯·®<À¯¼Ó>°è.
  • flow meter controlled vaporizer
    À¯·®Á¶Àý±âÈ­±â.
  • flow misregistration
    À¯µ¿ ¿Àµî·Ï
  • flow phenomena
    À¯µ¿ Çö»ó
  • flow related enhancement
    À¯µ¿ °ü·Ã Áõ°­
  • flow resistance
    È帧ÀúÇ×(¡­î½ù÷), À¯·®ÀúÇ×(¡­î½ù÷).
  • flow sensitive gradient echo sequence
    À¯µ¿ ¹Î°¨ °æ»ç ¿¡ÄÚ ¿¬¼â
  • flow signal
    À¯µ¿ ½ÅÈ£
  • flow velocity profile
    À¯¼Ó ºÐÆ÷»ó
  • flow void
    À¯µ¿ °ø¹é
  • flow void sign
    À¯µ¿ °ø¹é ¡ÈÄ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
FR failure rate; film-screen radiograph; fasciculus retroflexus; febrile reaction; feedback regulation;...
MEFV Maximal Expiratory Flow-Volume
MEF50 mean maximal expiratory flow
MEFV maximal expiratory flow volume
MFV maximal flow-volume [loop]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
MVV Maximal voluntary ventilation
MWD Maximal walking distance
MTD Maximal-tolerated doses
MAOD maximal accumulated oxygen deficit
MES maximal electroshock-induced seizure
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • rate dependent bundle branch block
    ½É¹Ú ¼ö ÀÇÁ¸¼º °¢ Â÷´Ü
  • rate of ablation
    Á¦°ÅÀ²
  • rate of polymerization
    ÁßÇÕ·ü
  • rate of teeth decayed
    ¿ì½Ä·ü
  • rate-limiting enzyme
    ¼Óµµ Á¶Àý È¿¼Ò
  • repetition rate
    ¹Ýº¹À²
  • respiratory rate
    È£ÈíÀ²
    ¼ºÀÎÀÇ °æ¿ì È£ÈíÀº 1ºÐ¿¡ 16~18ȸ ¾î¸°ÀÌ´Â 24~28ȸ Á¤µµ°¡ Á¤»óÀÌ´Ù.
  • sedimentation rate
    ħ°­À², ħ°­ ¼Óµµ
    µ¿ÀǾî=erythrocyte sedimentation rate.
  • stillbirth rate
    »ç»êÀ²
  • survival rate
    »ýÁ¸À²
  • toddler mortality rate
    À¯¾Æ »ç¸Á·ü
  • tooth mortality rate
    Ä¡¾Æ »ó½Ç·ü
  • turnover rate
    ±³Ã¼À², ±³Ã¼ ¼Óµµ, ±³´ëÀ²
  • water absorption rate
    ¼öºÐ Èí¼öÀ²
    Èí¼öÀ²Àº Èí¼ö·®°ú °ÇÁ¶ Áß·®°úÀÇ ºñ·Î Ç¥½ÃµÈ´Ù. Áï
  • water-air exposure rate
    ¼ö°øÁßÁ¶»ç¼±·®ºñ, ¹°-°ø±âÁßÁ¶»ç¼±·®ºñ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
metabolic clearance rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site.
(12 Dec 1998)
gross reproduction rate The average number of female children a woman would have if she survived to the end of her childbearing years and if, throughout that period, she were subject to a given set of age-specific fertility rates and a given sex ratio at birth; this rate provides a measure of the replacement fertility of a population in the absence of mortality.
(05 Mar 2000)
growth rate <biology, cell culture, ecology> The rate, or speed, at which the number of organisms in a population increases.
This can be calculated by dividing the change in the number of organisms from one point in time to another by the amount of time in the interval between the points of time.
The phrase is most often used to describe growth of cells or microorganisms in laboratory cultures and usually expressed as the generation time.
(21 Jun 2000)
growth rate of population <epidemiology> A measure of population change in the absence of migration, comprising addition of newborns and subtraction of deaths; the result is known as the natural rate of increase of the population; it is the difference between the crude birth rate and the crude death rate.
(05 Mar 2000)
mitotic rate The proportion of cells in a tissue that are undergoing mitosis, expressed as a mitotic index or, roughly, as the number of cells in mitosis in each microscopic high-power field in tissue sections.
(05 Mar 2000)
morbidity rate The sickness rate, the number of people who are sick or have a disease compared with the number who are well.
(09 Oct 1997)
mortality rate <statistics> The proportion of deaths in a population or to a specific number of the population.
(18 Nov 1997)
mortality rate, foetal The ratio of foetal deaths to the sum of the births (the live births + the foetal deaths) in that year. In the united states, the foetal mortality rate plummeted from 19.2 per 1,000 births in 1950 to 9.2 per 1,000 births in 1980.
(12 Dec 1998)
mortality rate, infant The number of children dying under a year of age divided by the number of live births that year. The infant mortality rate in the united states, which was 12.5 per 1,000 live births in 1980, fell to 9.2 per 1,000 live births in 1990.
(12 Dec 1998)
mortality rate, maternal The number of maternal deaths related to childbearing divided by the number of live births (or by the number of live births + foetal deaths) in that year. The maternal mortality rate in the united states in 1993 (and 1994) was 0.1 per 1,000 live births, or 1 mother dying per 10,000 live births.
(12 Dec 1998)
mortality rate, neonatal The number of children dying under 28 days of age divided by the number of live births that year. The neonatal mortality rate in the united states, which was 8.4 per 1,000 live births in 1980, declined to 5.8 per 1,000 live births in 1990.
(12 Dec 1998)
concordance rate The proportion of a random sample of pairs that are concordant for a trait of interest. A high rate of concordance may be generated in several ways, many of which may result from irrelevant bias; but broadly it is taken as evidence of causal connection (e.g., in the case of identical twins, a genetic component or in spouses of assortative mating).
(05 Mar 2000)
contact rate <epidemiology> The rate at which susceptibles meet infecteds. Usually measured as individuals per unit time.
(05 Dec 1998)
mutation rate The frequency with which a particular mutation appears in a population or the frequency with which any mutation appears in the whole genome of a population. Normally the context makes the precise use clear.
See: fluctuation analysis.
(18 Nov 1997)
critical rate A heart rate at which aberration or incomplete block will occur; a result of shortening of cycle length so that it barely includes the refractory period.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á